Dr Marco Gerlinger's team investigates how cancer evolution and plasticity lead to resistance to cancer drugs and immunotherapies, with the aim of designing better treatments that prevent drug resistance.
Dr Marco Gerlinger developed new tools to detect and track the evolution of cancer cells and of their microenvironment and better therapies which prevent the evolution of drug resistance. He holds an Honorary Consultant Medical Oncologist position at The Royal Marsden NHS Foundation Trust, where he treats patients with gastro-intestinal cancers. Based on the research in his lab, he performed clinical trials of novel immunotherapies that aimed to leverage the immune system to attack cancer cells.
Dr Gerlinger left the ICR on January 2022.